The purpose of this clinical trial is to study the therapeutic effect of black cumin water extract (Nigella sativa L.) on obesity and overweight
The worldwide prevalence of obesity has reached epidemic proportions mostly in low-income and transitional than in industrialized countries. Changes in dietary habits and sedentary lifestyles are known to be associated with changes in health and increased prevalence of chronic diseases in the population. The need to promote healthy nutrition for the population must be pursued vigorously, as the escalation of nutrition-related chronic degenerative diseases - once an urban phenomenon - has now spread to the rural population at an alarming rate. During the past decades efficacious strategies have been developed for prevention of these diseases. These strategies involve general lifestyle changes, which include, healthy diet, optimal weight, physical activity, moderate or no alcohol consumption, control of diabetes mellitus and in particular, treatment of obesity. Although the global market for satiety, fat burning and other weight management remedies has been grown, the awareness of the benefits of weight management ingredients is neither sufficient nor clearly perceived by consumer. Subsequently, the opportunities for scientifically-substantiated weight management ingredients regarding the natural and herbal dietary pattern are impressive. The seed of Nigella sativa (black cumin) is one of the most common traditional herbs for weight loss in the Middle East which is usually used as a spice as well as traditional medicine to treat a variety of health conditions especially inflammatory diseases and obesity. Furthermore, many of the components present in black cumin including polyphenols have been attributed to have anti-inflammatory and anti-obesity effect which further supports our hypothesis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
to be given orally in a dosage of 30 ml trice daily for 60 days
BP (blood pressure)
Change from Baseline in Systolic Blood Pressure at 12 weeks
Time frame: 0 and12 weeks
HR (heart rate)
Change from Baseline in heart rate at 12 weeks
Time frame: 0 and 12 weeks
Body water (percentage)
Change from Baseline in body water at 12 weeks
Time frame: 0 and 12 weeks
Fat free mass (percentage)
Change from Baseline in fat free mass at 12 weeks
Time frame: 0 and 12 weeks
Fat mass (percentage)
Change from Baseline in fat mass at 12 weeks
Time frame: 0 and 12 weeks
Bone mass
Change from Baseline in bone mass at 12 weeks
Time frame: 0 and 12 weeks
BMR (basic metabolic rate)
Change from Baseline in BMR at 12 weeks
Time frame: 0 and12 weeks
AMR (active metabolic rate)
Change from Baseline in AMR at 12 weeks
Time frame: 0 and 12 weeks
BMI (body mass index)
Change from Baseline in BMI at 12 weeks
Time frame: 0 and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
WHR (waist to hip ratio)
Change from Baseline in WHR at 12 weeks
Time frame: 0 and 12 weeks
MUAC (mid upper arm circumference)
Change from Baseline in MUAC at 12 weeks
Time frame: 0 and 12 weeks
Wrist circumference
Change from Baseline in wrist circumference at 12 weeks
Time frame: 0 and 12 weeks
Changes in appetite as measured by a 10-point visual analog scale (VAS)
Change from Baseline in VAS at 12 weeks
Time frame: 0 and 12 weeks